Description

This retrospective observational study investigates changes in taste perception, eating habits, and other behavioral aspects associated with the use of GLP-1 receptor agonists in patients undergoing treatment for weight loss. The study includes adults aged 18-60 years who have been treated at specialized nutrition centers in Italy during 2025-2026. Data are collected retrospectively from clinical records, dietary questionnaires, bioimpedance analysis for body composition, and metabolic assessments conducted before and after at least 12 weeks of treatment with GLP-1 agonists such as semaglutide or tirzepatide.

The primary objective is to evaluate the impact of GLP-1 agonist treatment on food preferences and taste perception changes. Secondary objectives include quantifying changes in body weight, body mass index (BMI), and body composition (fat mass and lean mass), assessing gastrointestinal side effects, measuring total energy expenditure and physical activity variations, and estimating treatment adherence and discontinuation reasons.

Data collection involves anonymized extraction of demographic, anthropometric, clinical, dietary, and behavioral information in accordance with GDPR and ethical guidelines. The analysis is performed using statistical methods including paired t-tests, Wilcoxon tests, and regression models adjusted for age, sex, baseline BMI, diabetes status, and concomitant medications.

This study is non-profit and does not involve additional costs or interventions beyond routine clinical care. Ethical approval is pending and will be obtained before the study initiation. All procedures will comply with local regulations and ethical guidelines.